{"nctId":"NCT01133704","briefTitle":"Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer","startDateStruct":{"date":"2000-05"},"conditions":["Hormone-Refractory Prostate Cancer"],"count":98,"armGroups":[{"label":"sipuleucel-T (APC8015)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: sipuleucel-T"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: APC-Placebo"]}],"interventions":[{"name":"sipuleucel-T","otherNames":[]},{"name":"APC-Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically documented adenocarcinoma of the prostate\n* Metastatic disease as evidenced by soft tissue and/or bony metastases\n* Prostate-specific antigen value of at least 5 ng/mL\n* Tumor progression while on hormonal therapy\n* Castration levels of testosterone (defined as less than 50 ng/dL)\n* Life expectancy of at least 16 weeks\n* Adequate hematologic, renal, and liver function\n\nExclusion Criteria:\n\n* Visceral organ metastases\n* Metastatic disease expected to be in need of radiation therapy within 4 months.\n* Concurrent therapy with experimental agents","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Time to Disease Progression","description":"Overall time to disease progression in subjects with asymptomatic metastatic hormone-refractory prostate cancer treated with sipuleucel-T (APC8015) compared to overall time to disease progression in subjects treated with placebo.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"9.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Subjects were followed for 3 years from the time of randomization or until death.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0","spread":null},{"groupId":"OG001","value":"15.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":65},"commonTop":["Chills","Fatigue","Pyrexia","Back Pain","Arthralgia"]}}}